Tonix Pharmaceuticals Holding (TNXP) Change in Receivables (2024 - 2026)

Tonix Pharmaceuticals Holding has reported Change in Receivables for 3 years, with the latest figure at $3.0 million in Q2 2026.

• On a quarterly basis, Change in Receivables rose 401.01% year-over-year to $3.0 million in Q2 2026; TTM through Jun 2026 was $9.5 million, a 1033.86% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, down 28.89% from the prior year.
• Change in Receivables was $3.0 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $2.5 million in the prior quarter.
• The five-year high for Change in Receivables was $3.0 million in Q2 2026, with the low at -$1.3 million in Q4 2024.
• Average Change in Receivables over 3 years is $1.1 million, with a median of $1.4 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Change in Receivables retreated 27.39% in 2025, then soared 786.79% in 2026.
• Over 3 years, Change in Receivables stood at -$1.3 million in 2024, then surged by 314.7% to $2.8 million in 2025, then climbed by 7.06% to $3.0 million in 2026.
• The last three Change in Receivables figures came in at $3.0 million (Q2 2026), $2.5 million (Q1 2026), and $2.8 million (Q4 2025), per Business Quant data.